AR050703A1 - Compuestos heterociclicos antiviricos - Google Patents
Compuestos heterociclicos antiviricosInfo
- Publication number
- AR050703A1 AR050703A1 ARP050103479A ARP050103479A AR050703A1 AR 050703 A1 AR050703 A1 AR 050703A1 AR P050103479 A ARP050103479 A AR P050103479A AR P050103479 A ARP050103479 A AR P050103479A AR 050703 A1 AR050703 A1 AR 050703A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- optionally substituted
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910003827 NRaRb Inorganic materials 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004405 heteroalkoxy group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 101100203602 Hypocrea jecorina (strain QM6a) sor7 gene Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- -1 imidazolinylmethyl Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 150000002545 isoxazoles Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Los siguientes compuestos son inhibidores de la polimerasa del virus de la hepatitis C (HCV). Se describen además composiciones y métodos para el tratamiento de enfermedades mediadas por el HCV y para inhibir la replicacion de la hepatitis. Se describen también procesos para la obtencion de los compuestos y de los compuestos intermedios de síntesis empleados en el proceso. Reivindicacion 1: Un compuesto segun la formula (1), en la que: A, se elige entre el grupo formado por las formulas (2), X es CH o N; Y es H, un metal alcalino o NH4+; X6 es -O-, -NR6 o X6 está ausente; R1 con independencia de su aparicion se elige entre el grupo formado por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilC3-7- alquiloC1-4, alcoxi C1-6, fenilo opcionalmente sustituido, fenil-alquilo C1-6 opcionalmente sustituido, hidroxialquilo C1-6, alcoxiC1-3-alquiloC1-6, fenoxi opcionalmente sustituido, fenil-alcoxiC1-3 opcionalmente sustituido, heteroalcoxi C1-6, hidroxilo, halogeno, -X1(CH2)oCOR5, (CH2)oCOR5, -X1(CH2)oSO2R7, -(CH2)oSOR7, -XC(=O)R9, -NR6SO2R7, -X4(CH2)rNRa'Rb', -CO2R6, X4NRaRb, nitro y ciano; dichos grupos fenilo opcionalmente sustituido están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-3, alquenilo C2-4, alquinilo C2-4, alcoxi C1-3, fenoxi, haloalquilo C1-3, hidroxi, halogeno, NRaRb, ciano y nitro; R2 se elige con independencia de su aparicion entre el grupo formado por alquilo C1-6, alquenilo C3-6, alquinilo C3-6, piridinilmetilo, imidazolinilmetilo, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-3, heteroalquilo C1-6 y fenil-alquiloC1-3; dicho fenilo está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-3, alquenilo C2-4, alquinilo C2-4, alcoxi C1-3, fenoxi, haloalquilo C1-3, hidroxi, halogeno, NRaRb, ciano y nitro; R3 con independencia de su aparicion se elige entre el grupo formado por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-4, alcoxi C1-6, halogeno; R4 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-4, heteroalquilo C1-6, fenilo o fenilalquilo C1-4, dicho fenilo está opcionalmente sustituido con independencia entre sí de una a tres veces por restos R3; R5 es hidroxilo, alcoxi C1-6, -NRaRb, fenilo o heteroalcoxi C1-6; R6 es hidrogeno o alquilo C1- 6; R7 es alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-4, -NRaRb, -NR6(CH2)p-fenilo, -NHBoc, heteroalquilo C1-6, -X2(CH2)oCOR5, isoxazol opcionalmente sustituido, fenilo o fenil-alquiloC1-3; dicho fenilo y dicho isoxazol están sustituidos con independencia entre sí de una a tres veces por sustituyentes alquilo C1-3, alcoxi C1-3, halogeno, nitro o ciano; R8 es R6 o acilo C1-6; R9 es alquilo C1-6, cicloalquilo C3-7, fenilo, NRaRb, o OR4 en los que R4 no es hidrogeno y dicho fenilo está opcionalmente sustituido de una a tres veces por restos R3; R10 es fenilo o piridinilo; dicho fenilo y dicho piridinilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos entre el grupo formado por alquilo C1- 3, alcoxi C1-3, haloalquilo C1-3, halogeno, NRaRb, ciano y nitro; Ra y Rb son i) con independencia entre sí hidrogeno, alquilo C1-6 o heteroalquilo C1-6, o ii) juntos son (CH2)q, -(CH2)2OC(=O)- o (CH2)2X3(CH2)2; Ra' y Rb' con independencia entre sí son i) hidrogeno, alquilo C1-6 o heteroalquilo C1-6, o ii) Ra es -SO2R4, -SO2NRaRb o -COR9 y Rb es hidrogeno; iii) Ra' y Rb' juntos son (CH2)q o (CH2)2X3(CH2)2; X1 es O, S(O)p, C(=O) o NR6; X2 es NR6 o un enlace; X3 es -O-, C=O o NR8; X4 es X1 o un enlace; X5 es NR6 u O; m y n con independencia entre sí son un numero de cero a tres; o y r con independencia entre sí son un numero de uno a seis; p es un numero de cero a dos; q es un numero de cuatro a siete; y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60377104P | 2004-08-23 | 2004-08-23 | |
| US67771005P | 2005-05-04 | 2005-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050703A1 true AR050703A1 (es) | 2006-11-15 |
Family
ID=35180855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103479A AR050703A1 (es) | 2004-08-23 | 2005-08-19 | Compuestos heterociclicos antiviricos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7479489B2 (es) |
| EP (1) | EP1786807B1 (es) |
| JP (1) | JP4624419B2 (es) |
| KR (1) | KR100847181B1 (es) |
| CN (1) | CN101048403B (es) |
| AR (1) | AR050703A1 (es) |
| AT (1) | ATE437875T1 (es) |
| AU (1) | AU2005276648A1 (es) |
| BR (1) | BRPI0514591A (es) |
| CA (1) | CA2577528A1 (es) |
| DE (1) | DE602005015732D1 (es) |
| ES (1) | ES2327764T3 (es) |
| IL (1) | IL181219A0 (es) |
| MX (1) | MX2007002238A (es) |
| NO (1) | NO20071162L (es) |
| RU (1) | RU2007110531A (es) |
| SG (1) | SG137868A1 (es) |
| TW (1) | TWI296626B (es) |
| WO (1) | WO2006021340A1 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066079A2 (en) | 2004-12-17 | 2006-06-22 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| JP2009526808A (ja) * | 2006-02-17 | 2009-07-23 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| EP2038286B1 (en) * | 2006-06-22 | 2017-03-08 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
| US20080090814A1 (en) * | 2006-06-22 | 2008-04-17 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| SI2084175T1 (sl) | 2006-10-10 | 2011-05-31 | Medivir Ab | Hcv nukleozidni inhibitor |
| WO2008073987A1 (en) * | 2006-12-12 | 2008-06-19 | Anadys Pharmaceuticals, Inc. | Saturated fused [1,2-b] pyridazinone compounds |
| TW200840572A (en) * | 2006-12-12 | 2008-10-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
| US20080188466A1 (en) * | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| WO2008082725A1 (en) * | 2006-12-29 | 2008-07-10 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| US20080227774A1 (en) * | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| UA100120C2 (en) * | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
| ITMI20071012A1 (it) * | 2007-05-18 | 2008-11-19 | St Microelectronics Srl | Dispositivo di memoria migliorato a veloce programmazione |
| US7834009B2 (en) * | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
| US7932240B2 (en) * | 2007-08-31 | 2011-04-26 | Idenix Pharmaceuticals, Inc. | Phosphadiazine HCV polymerase inhibitors IV |
| GB0800855D0 (en) | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
| AU2009241514A1 (en) * | 2008-04-15 | 2009-11-05 | Intermune, Inc. | Novel inhibitors of hepatitis C virus replication |
| TWI438206B (zh) | 2008-06-10 | 2014-05-21 | Anadys Pharmaceuticals Inc | 〔１，２，４〕噻二１，１二氧化物化合物 |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| BRPI0920513A2 (pt) * | 2008-09-26 | 2019-09-24 | F Hoffamann La Roche Ag | derivados de pirina ou pirazina para tratar hcv |
| TW201026675A (en) * | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
| ES2435799T3 (es) * | 2008-10-09 | 2013-12-23 | Anadys Pharmaceuticals, Inc. | Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales |
| MX2011004396A (es) * | 2008-10-29 | 2011-05-25 | Basf Se | Piridinas sustituidas con accion herbicida. |
| WO2010049331A1 (en) * | 2008-10-30 | 2010-05-06 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral arylpyridone derivatives |
| SG172778A1 (en) * | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| SG174252A1 (en) | 2009-03-06 | 2011-10-28 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| TW201103545A (en) | 2009-06-24 | 2011-02-01 | Hoffmann La Roche | Heterocyclic antiviral compound |
| CA2768924A1 (en) | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| KR20120092142A (ko) | 2009-10-28 | 2012-08-20 | 애나디스 파마슈티칼스, 인코포레이티드 | 중수소화 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물 |
| TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
| CA2778206A1 (en) | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| RS54368B1 (sr) | 2010-03-31 | 2016-04-28 | Gilead Pharmasset Llc | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| SG11201600919UA (en) | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| RU2626239C1 (ru) * | 2016-10-11 | 2017-07-25 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Фторированные 4-фурфурил-3,4-дигидро-2н-бензо[1,4]тиазин-1,1-диоксиды, обладающие высокой аритмической активностью |
| RU2627499C1 (ru) * | 2016-10-11 | 2017-08-08 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | 4-арил(гетарил)метил-замещенные 8-циклопентиламино-5,7-дифтор-3,4-дигидро-2н-бензо[1,4]тиазин-1,1-диоксиды, обладающие гипертензивным действием |
| CN110724102B (zh) * | 2019-10-25 | 2021-06-15 | 华南农业大学 | 一种含四氢罂粟碱-3-羧酸甲酯的多酚类化合物及其制备方法和应用 |
| CN112510260B (zh) * | 2020-11-27 | 2022-11-04 | 珠海市赛纬电子材料股份有限公司 | 电解液添加剂、非水电解液和锂离子电池 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| FR2691459B1 (fr) * | 1992-05-25 | 1995-06-09 | Adir | Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU3147500A (en) * | 1999-03-12 | 2000-10-04 | Novo Nordisk A/S | Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use |
| WO2001001933A2 (en) * | 1999-07-06 | 2001-01-11 | The Procter & Gamble Company | Pre-formed, self-adhesive sheet devices suitable for topical application |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| AU2002359320A1 (en) * | 2001-10-29 | 2003-05-12 | Smithkline Beecham Corporation | Novel anit-infectives |
| AU2002365198A1 (en) * | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
| AU2003248566A1 (en) * | 2002-05-24 | 2003-12-12 | Smithkline Beecham Corporation | Novel anti-infectives |
| US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
| WO2004041818A1 (en) | 2002-11-01 | 2004-05-21 | Abbott Laboratories | Anti-infective agents |
| US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| US20040162285A1 (en) * | 2002-11-01 | 2004-08-19 | Pratt John K. | Anti-infective agents |
| WO2004052312A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
| WO2004052313A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
| WO2004058150A2 (en) | 2002-12-17 | 2004-07-15 | Smithkline Beecham Corporation | Anti-infectives |
| WO2005019191A2 (en) | 2003-08-25 | 2005-03-03 | Abbott Laboratories | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c |
-
2005
- 2005-08-16 KR KR1020077004165A patent/KR100847181B1/ko not_active Expired - Fee Related
- 2005-08-16 BR BRPI0514591-0A patent/BRPI0514591A/pt not_active IP Right Cessation
- 2005-08-16 JP JP2007528687A patent/JP4624419B2/ja not_active Expired - Fee Related
- 2005-08-16 AT AT05777382T patent/ATE437875T1/de not_active IP Right Cessation
- 2005-08-16 AU AU2005276648A patent/AU2005276648A1/en not_active Abandoned
- 2005-08-16 EP EP05777382A patent/EP1786807B1/en not_active Expired - Lifetime
- 2005-08-16 MX MX2007002238A patent/MX2007002238A/es not_active Application Discontinuation
- 2005-08-16 CN CN2005800360576A patent/CN101048403B/zh not_active Expired - Fee Related
- 2005-08-16 ES ES05777382T patent/ES2327764T3/es not_active Expired - Lifetime
- 2005-08-16 RU RU2007110531/04A patent/RU2007110531A/ru not_active Application Discontinuation
- 2005-08-16 SG SG200718130-8A patent/SG137868A1/en unknown
- 2005-08-16 CA CA002577528A patent/CA2577528A1/en not_active Abandoned
- 2005-08-16 DE DE602005015732T patent/DE602005015732D1/de not_active Expired - Lifetime
- 2005-08-16 WO PCT/EP2005/008855 patent/WO2006021340A1/en not_active Ceased
- 2005-08-19 AR ARP050103479A patent/AR050703A1/es unknown
- 2005-08-22 TW TW094128556A patent/TWI296626B/zh not_active IP Right Cessation
- 2005-08-22 US US11/208,962 patent/US7479489B2/en not_active Expired - Fee Related
-
2007
- 2007-02-08 IL IL181219A patent/IL181219A0/en unknown
- 2007-03-01 NO NO20071162A patent/NO20071162L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101048403B (zh) | 2010-06-16 |
| TW200621761A (en) | 2006-07-01 |
| MX2007002238A (es) | 2007-04-20 |
| KR100847181B1 (ko) | 2008-07-17 |
| DE602005015732D1 (de) | 2009-09-10 |
| SG137868A1 (en) | 2007-12-28 |
| EP1786807B1 (en) | 2009-07-29 |
| JP4624419B2 (ja) | 2011-02-02 |
| KR20070034637A (ko) | 2007-03-28 |
| EP1786807A1 (en) | 2007-05-23 |
| ES2327764T3 (es) | 2009-11-03 |
| CN101048403A (zh) | 2007-10-03 |
| IL181219A0 (en) | 2007-07-04 |
| US7479489B2 (en) | 2009-01-20 |
| RU2007110531A (ru) | 2008-09-27 |
| CA2577528A1 (en) | 2006-03-02 |
| TWI296626B (en) | 2008-05-11 |
| US20060040927A1 (en) | 2006-02-23 |
| AU2005276648A1 (en) | 2006-03-02 |
| ATE437875T1 (de) | 2009-08-15 |
| NO20071162L (no) | 2007-04-17 |
| BRPI0514591A (pt) | 2008-06-17 |
| WO2006021340A1 (en) | 2006-03-02 |
| JP2008510747A (ja) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050703A1 (es) | Compuestos heterociclicos antiviricos | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
| AR011101A1 (es) | Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| DOP2002000333A (es) | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
| AR039413A1 (es) | Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| AR054787A1 (es) | Derivados de piperidinas utiles como antagonistas de histamina h3 | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| EA200401053A1 (ru) | Оксо-азабициклические соединения | |
| EA200300891A1 (ru) | Ингибиторы протеазы вич широкого спектра действия на основе сульфонамидов 2-(замещенных-амино) бензотиазолов | |
| AR040332A1 (es) | Derivados de acido benzoico como moduladores de ppar alfa y gamma | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR040133A1 (es) | Derivados de n-acilamino bencil eter | |
| CO5550437A2 (es) | Compuestos quimicos | |
| EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| AR041405A1 (es) | Derivados de (+) - trans - isomeros de ( 1- fosfonometoxi - 2 alquiciclopropil) metil nucleosido, un procedimiento para la preparacion de esteroisomeros de los mismos y utilizacion de agentes antivirales de los mismos | |
| ATE428693T1 (de) | Prostaglandinsynthese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |